Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Societies Agree to Introduce Unified Cancer Specialist Certification System
July 11, 2005
- Mr Murakami Stresses Need for Daiichi Sankyo to Boost Share Price
July 11, 2005
- REGULATORY NEWS IN BRIEF
July 11, 2005
- Sankyo's Shareholders Approve Integration with Daiichi
July 11, 2005
- NDA Review Delayed in 2004: OPIR News
July 11, 2005
- STATISTICS
July 11, 2005
- Study Group on Clinical Trials Holds 4th Meeting
July 11, 2005
- SURVEY 2 articles
July 11, 2005
- Discussions to Center on Low-priced Old Drugs, Price Adjustment Based on Overseas Prices
July 11, 2005
- Clinical Trial Registration/Announcement System Started Operation on July 1
July 11, 2005
- Mr Niwa Reconfirms His Opinions on NHI Drug Pricing
July 11, 2005
- NEW PRODUCTS
July 11, 2005
- WORLD BUSINESS
July 11, 2005
- BUSINESS NEWS IN BRIEF
July 11, 2005
- Basic Policy 2005 for Economic/Fiscal Management and Structural Reform Approved
July 4, 2005
- Common IRB Proposed in Special Regulatory Reform Zone in Osaka
July 4, 2005
- Chuikyo Listens to NHI Drug Pricing Organization on Problems with NHI Pricing Rule
July 4, 2005
- NHO to Revise Its Clinical Trial Cost Calculation Method
July 4, 2005
- STATISTICS
July 4, 2005
- Let the Market Decide Prices of New Drugs: Mr Niwa
July 4, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…